The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is estimated to be valued at US$ 748.80 million in 2022 and is expected to exhibit a CAGR of 31.1% over the forecast period 2020-2027, as highlighted in a new report published by Coherent Market Insights. Market Overview: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart muscle disease caused by the buildup...
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian